Cymbalta Approved for Chronic Joint and Muscle
FRIDAY, Nov. 5 (HealthDay News) -- Cymbalta (duloxetine
hydrochloride) has received expanded approval from the U.S. Food
and Drug Administration to treat chronic musculoskeletal pain,
stemming from conditions including lower back pain and
Since its approval as an antidepressant in 2004, some 30 million
people in the United States have used the drug, the agency said in
a news release. The FDA also has sanctioned Cymbalta for the
treatment of diabetic pain, generalized anxiety disorder and
The most common side effects from Cymbalta use include nausea,
dry mouth, insomnia, drowsiness, constipation, fatigue, and
dizziness. More serious adverse reactions have included liver
damage, allergic reaction, pneumonia, depressed mood, and suicidal
thoughts and behavior, the agency said.
The FDA has also warned that Cymbalta should never be used in
patients who have recently taken a type of antidepressant called an
MAOI, or Mellaril (thioridazine), or who have uncontrolled
Cymbalta is produced by Eli Lilly and Co., based in
National Library of Medicine has more about this
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.